Literature DB >> 14974920

Fibrous bodies are associated with lower GH production and decreased expression of E-cadherin in GH-producing pituitary adenomas.

Hiroshi Nishioka1, Jo Haraoka, Kiyohiro Akada.   

Abstract

OBJECTIVE: A retrospective study was conducted in order to elucidate the clinicopathological significance of fibrous bodies, a hallmark of the sparsely granulated variant of GH-producing pituitary adenomas.
METHODS: A total of 37 acromegalic patients, 14 men and 23 women, with pure GH adenomas were studied. Immunohistochemistry was performed with antibodies specific for cytokeratin 8 and 18 (CAM5.2), GH, prolactin and E-cadherin. The tumour volume was estimated with high-resolution magnetic resonance imaging.
RESULTS: The percentages of adenoma cells with dot-like immunoreactivity for CAM5.2, fibrous bodies, were variable, ranging continuously from 0 to 100%. An increased percentage was associated with a lower basal GH level per unit tumour volume, a lower GH response to a bromocriptine suppression test, decreased immunoreactivities for GH and prolactin, and a decreased expression of E-cadherin immunoreactivity.
CONCLUSION: GH adenomas could not be distinctly separated into those with or without fibrous bodies. Decreased expression of E-cadherin may be involved in formation of fibrous bodies and result in lower GH production.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14974920     DOI: 10.1046/j.1365-2265.2003.01921.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  6 in total

Review 1.  Pathology of GH-producing pituitary adenomas and GH cell hyperplasia of the pituitary.

Authors:  Luis V Syro; Fabio Rotondo; Carlos A Serna; Leon D Ortiz; Kalman Kovacs
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

2.  Stereotactic radiosurgery for acromegaly: outcomes by adenoma subtype.

Authors:  Cheng-Chia Lee; Mary Lee Vance; M Beatriz Lopes; Zhiyuan Xu; Ching-Jen Chen; Jason Sheehan
Journal:  Pituitary       Date:  2015-06       Impact factor: 4.107

Review 3.  Clinical Impact of the Current WHO Classification of Pituitary Adenomas.

Authors:  W Saeger; J Honegger; M Theodoropoulou; U J Knappe; C Schöfl; S Petersenn; R Buslei
Journal:  Endocr Pathol       Date:  2016-06       Impact factor: 3.943

4.  E-cadherin expression is associated with somatostatin analogue response in acromegaly.

Authors:  Eva Venegas-Moreno; Alvaro Flores-Martinez; Elena Dios; Mari C Vazquez-Borrego; Alejandro Ibañez-Costa; Ainara Madrazo-Atutxa; Miguel A Japón; Justo P Castaño; Raúl M Luque; David A Cano; Alfonso Soto-Moreno
Journal:  J Cell Mol Med       Date:  2019-03-06       Impact factor: 5.310

5.  Association of Pathology Markers with Somatostatin Analogue Responsiveness in Acromegaly.

Authors:  George Kontogeorgos; Vyron Markussis; Eleni Thodou; Efi Kyrodimou; Theodossia Choreftaki; Panagiotis Nomikos; Kostas I Lampropoulos; Stylianos Tsagarakis
Journal:  Int J Endocrinol       Date:  2022-09-26       Impact factor: 2.803

6.  Clinicopathological Features of Growth Hormone-Producing Pituitary Adenomas in 242 Acromegaly Patients: Classification according to Hormone Production and Cytokeratin Distribution.

Authors:  Ryosuke Mori; Naoko Inoshita; Junko Takahashi-Fujigasaki; Tatsuhiro Joki; Hiroshi Nishioka; Toshiaki Abe; Takeshi Fujii; Shozo Yamada
Journal:  ISRN Endocrinol       Date:  2013-01-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.